Background/Objectives: Robust, state-level LGBTQ+ health surveillance is scarce in Kentucky, limiting evidence-based healthcare planning and policy. We aimed to evaluate the feasibility and early public-health utility of a community-partnered annual survey and compare selected mental health stressors between Kentucky and non-Kentucky respondents. Methods: We conducted a cross-sectional online survey (13 April–15 July 2024) developed with a statewide LGBTQ+ nonprofit. Recruitment occurred via organizational channels and community events. A content warning preceded the survey, which was administered via Qualtrics. Data quality was screened using reCAPTCHA. We assessed feasibility metrics including recruitment and completion rates. Mental health stressors were captured with a six-item scale. Group differences were estimated with Welch’s t-tests. Results: Of 3852 survey starts, 1559 were retained as analyzable completes (completion rate: 40.47%), with 78.7% residing in-state. Initial analysis revealed a significant divergence in mental health patterns: while Kentucky participants reported lower stress regarding their personal mental health, they reported significantly higher stress stemming from socio-political issues like homophobia and transphobia compared to out-of-state respondents. Conclusions: An annual, community-partnered surveillance platform is a feasible strategy for generating actionable mental health signals relevant to healthcare. These findings will inform targeted outreach and guide health system partnerships to enhance LGBTQ+-affirming care in Kentucky.

Background: Veterans with HIV/AIDS (VWH) frequently report alcohol misuse, which can impact antiretroviral therapy (ART) adherence and lead to poorer clinical outcomes. The TRAC (Tracking and Reducing Alcohol Consumption) intervention was developed to help VWH reduce alcohol use and its associated consequences. TRAC is delivered via mobile device, incorporates eight counseling sessions based in cognitive behavioral therapy and motivational interviewing, and utilizes mobile surveys and breathalyzers for daily monitoring of alcohol and ART use. Methods: We conducted a pilot randomized waitlist-controlled trial ( N = 50). Participants were allocated to an immediate intervention group ( N = 26), which received the TRAC intervention and completed twice-daily monitoring of alcohol and ART use for 8 weeks, or to a waitlist-control ( n = 24), which started TRAC after 8 weeks. Participants provided ratings of intervention sessions and completed questionnaires assessing alcohol use, ART adherence, and treatment self-efficacy at baseline, 8, 16, and 24 weeks. Analyses included correlations and descriptive statistics for examining feasibility and acceptability, difference-in-differences analyses to compare changes between groups at the 8-week timepoint, matched pair tests to assess changes in alcohol use during the intervention, and general linear models to investigate long-term effects on outcomes with a pooled sample. Results: Results indicated high feasibility and acceptability: 84% of participants were retained through the intervention and all follow-ups, average intervention session ratings were 9.6 (out of 10), and participants completed a median of 85% and 78% of mobile surveys and breathalyzer readings, respectively. While not statistically significant due to low power, there was a trend of decreased binge drinking episodes and fewer missed HIV medication doses in the intervention group compared to control. When pooling data among participants from both groups to examine long-term effects, TRAC was associated with reductions in several drinking-related outcomes. Conclusions: High acceptability and feasibility, as well as preliminary evidence that the intervention may reduce alcohol use relative to control, suggest that the TRAC intervention is promising for VWH and warrants further evaluation in a randomized controlled trial with adequate power to detect effects. If shown to be efficacious, TRAC has potential to be a highly scalable and acceptable intervention for delivery among VWH. Trial registration: This study was registered on ClinicalTrials.gov, #NCT03746600. Registration date: 09/24/2018.